Supplemental cohort of 12 Japanese patients to be added to global Phase 3 hypothalamic obesity trial, with dosing expected to begin in third quarter of.
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Get Free Report) EVP Yann Mazabraud sold 1,594 shares of the company’s stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $51.38, for a total value of $81,899.72. Following the completion of the transaction, the executive vice president now directly owns 7,702 […]
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Get Free Report) CFO Hunter C. Smith sold 1,209 shares of the business’s stock in a transaction on Monday, February 12th. The stock was sold at an average price of $51.38, for a total transaction of $62,118.42. Following the transaction, the chief financial officer now directly owns 80,413 shares in […]
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Get Free Report) EVP Yann Mazabraud sold 1,594 shares of the stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $51.38, for a total value of $81,899.72. Following the sale, the executive vice president now owns 7,702 shares of the company’s stock, […]
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Get Free Report) insider Joseph Shulman sold 1,089 shares of the business’s stock in a transaction that occurred on Wednesday, February 14th. The stock was sold at an average price of $50.01, for a total transaction of $54,460.89. Following the sale, the insider now directly owns 30 shares of the […]